Cochlear (ASX:COH) Valuation After Profit Drop Nexa Delays And Lowered Outlook

Simply Wall St.

Yesterday

Cochlear (ASX:COH) is back in focus after its half year result showed net income of A$161.5 million and a lower full year profit outlook, alongside contracting delays for the new Nucleus Nexa system. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2612458671"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612458671\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612458671?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-02-17 16:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612458671","market":"us","top_or_hot":-1,"title":"Cochlear (ASX:COH) Valuation After Profit Drop Nexa Delays And Lowered Outlook","media":"Simply Wall St.","content":"<div>\n<p>Cochlear (ASX:COH) is back in focus after its half year result showed net income of A$161.5 million and a lower full year profit outlook, alongside contracting delays for the new Nucleus Nexa system. ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-asxcoh-valuation-after-profit-drop-nexa-delays-and\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cochlear (ASX:COH) Valuation After Profit Drop Nexa Delays And Lowered Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCochlear (ASX:COH) Valuation After Profit Drop Nexa Delays And Lowered Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-17 16:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-asxcoh-valuation-after-profit-drop-nexa-delays-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cochlear (ASX:COH) is back in focus after its half year result showed net income of A$161.5 million and a lower full year profit outlook, alongside contracting delays for the new Nucleus Nexa system. ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-asxcoh-valuation-after-profit-drop-nexa-delays-and\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COH.AU","symbol_name":"COCHLEAR LTD","start_time":0,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-asxcoh-valuation-after-profit-drop-nexa-delays-and","article_id":"2612458671","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-asxcoh-valuation-after-profit-drop-nexa-delays-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612458671","pubTimestamp":1771316188,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Cochlear (ASX:COH) is back in focus after its half year result showed net income of A$161.5 million and a lower full year profit outlook, alongside contracting delays for the new Nucleus Nexa system.\nSee our latest analysis for Cochlear.\nThe sharp post earnings selloff has left Cochlear at a share price of A$199.81, with a 7 day share price return of 22.22% and a 1 year total shareholder return of 25.96%. This signals fading momentum as investors reassess risks around Nexa adoption and the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"COH.AU":"COCHLEAR LTD","BK7007":"医疗保健设备"},"translate_title":"Cochlear(ASX：COH)利润下降后估值Nexa延迟并下调前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COH.AU":1.5},"content_text":"Cochlear (ASX:COH) is back in focus after its half year result showed net income of A$161.5 million and a lower full year profit outlook, alongside contracting delays for the new Nucleus Nexa system. See our latest analysis for Cochlear. The sharp post earnings selloff has left Cochlear at a share price of A$199.81, with a 7 day share price return of 22.22% and a 1 year total shareholder return of 25.96%. This signals fading momentum as investors reassess risks around Nexa adoption and the lower profit outlook. If Cochlear's recent profit and guidance reset has you rethinking concentration risk, it could be a good time to broaden your watchlist with our 10 healthcare AI stocks. With Cochlear now trading well below recent levels and carrying a weak value score of 2, despite analyst targets sitting higher than the current A$199.81 price, is the recent selloff an opportunity or is future growth already reflected? AdvertisementMost Popular Narrative: 33.8% Undervalued Against Cochlear's last close of A$199.81, the most followed narrative points to a fair value of A$301.76, putting a sizeable gap between price and modeled worth under its assumptions.  The launch of the Nexa system, the world's first smart cochlear implant, is expected to drive market share gains in developed markets due to strong differentiation, surgeon enthusiasm, and planned price increases, likely boosting revenue and average selling prices (ASPs) starting in 2H FY26.  Read the complete narrative. Read the complete narrative. Want to see what sits behind that valuation gap? The narrative leans on a mix of rising earnings, firm margins and a premium future earnings multiple. Curious how those pieces fit together and what they imply for Cochlear at A$199.81 versus A$301.76? Result: Fair Value of A$301.76 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story can change quickly if Nexa adoption is slower than analysts expect, or if pricing pressure in key markets drags on margins more than modeled. Find out about the key risks to this Cochlear narrative. Another View Using Market Ratios The first narrative leans on earnings forecasts and a premium future multiple to suggest Cochlear looks undervalued around A$199.81. On current numbers though, the market is already paying a steep P/E of 37.8x, compared with 30.4x for peers and 27.8x for the broader Global Medical Equipment group, even if our fair ratio work points to 44.1x as a level the market could move toward. That gap cuts both ways, so you need to ask whether you are more comfortable with the upside case or the risk that sentiment cools first. See what the numbers say about this price — find out in our valuation breakdown. ASX:COH P/E Ratio as at Feb 2026Next Steps If this mix of caution and optimism around Cochlear has you unsure, do not wait for consensus to form. Instead, review the underlying positives in our 2 key rewards. Looking for more investment ideas? If Cochlear is only one piece of your portfolio puzzle, do not stop here. Let the screener surface other angles you might be missing.  Spot potential mispricings early by scanning our 9 high quality undervalued stocks that pair solid fundamentals with room for sentiment to catch up. Strengthen your income stream by reviewing 9 dividend fortresses that prioritise higher yields with a focus on durability. Sleep easier at night by filtering for 5 resilient stocks with low risk scores that score well on financial health and volatility.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}